Japan Approval Sought For Sprycel As First-Line Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Japan is the target of a U.S.-based Bristol-Myers Squibb effort to expand the cancer-treatment indications for its Sprycel (dasatinib)